Serum-free, Xeno-free, no exogenous growth factors.
No need to add serum replacement, supports rapid proliferation and high-density culture of T cells.
Suitable for various T cell activation methods, can support stable culture for extended periods (>14 days).
Supports the expansion and culture of various types of T cells (CAR-T, TCR-T, γδT/CAR-γδT, TIL, etc.).
Available in both bottle and bag formats, compatible with closed cell culture systems.
Completely independently developed, with stable supply, GMP standard, DMF filing (file number 037572), and supports clinical application submissions and commercialization
a serum-free, xeno-free, exogenous growth factor-free, and phenol red-free medium specifically designed for the maintenance and expansion of T cells
a serum-free and xeno-free medium designed for the in vitro expansion of human T lymphocytes.
a serum-free and xeno-free medium designed for the in vitro expansion of human T lymphocytes.
| Product | Cat.No | size | Phenol red | Note |
|---|---|---|---|---|
| OptiVitro T | TE000-N022 | 1L | Y | Comparable to Gibco, our product meets higher demands for viability, expansion, and phenotyping of T cells. |
| TE000-N032 | 1L | N | ||
| TE000-N072 | 2L，Bag | N | ||
| OptiVitro TE07 | TE000-N082 | 1L | N | Optimized for in vitro transduction and expansion |
1000L Fully-automatic Liquid Filling line
Stainless steel liquid blending system
CGT serum-free medium has facilitated the successful approval of IND applications for multiple clients in both China and the United States by FDA and CDE, covering multiple technical pipelines such as TCR-T, TIL, γδ-T, CAR-T, UCAR-T, and general-purpose NK cells.
| Pepline | Type | Indications | Authorization | Date | Status |
|---|---|---|---|---|---|
| BRL03 | TCR-T | Advanced solid tumors (lung cancer, advanced stage, etc.) | FDA | 2023.9.9 | Approved |
| BRL03 | TCR-T | Advanced solid tumors (lung cancer, advanced stage, etc.) | CDE | 2023.10.25 | Accepting |
| 2024.1.15 | Approved | ||||
| BST02 | TIL | Liver cancer | FDA | 2023.10.26 | Approved |
| BST02 | TIL | Liver cancer | CDE | 2023.11.3 | Accepting |
| NK510 | Base Editing Directed NK | Advanced solid tumors | CDE | 2024.07.29 | Approved |
| γδ T Cell(GD Kongming) | γδ-T | Hepatocellular Carcinoma | CDE | 2024.01.31 | Approved |
| NK510 | Base Editing Directed NK | Advanced solid tumors | FDA | 2024.11.30 | Approved |
| UC101 | UCAR-T | CD19 | FDA | 2025.01.24 | Approved |
| UTAA09 | UCAR-Vδ1T | B-ALL | CDE | 2025.01.23 | Approved |
| BRG01 | CAR-T | EVB | FDA | 2025.01.31 | Change Approved |
| SA102 | CAR-T | BCMA | CDE | 2025.06.18 |
T Cell viability was determined every 2-3 days throughout the culture in OptiVitro® T cell serum-free Medium and medium1. Data represents the mean of three replicates for each independent tests.
T Cell density was tested every 2-3 days throughout the culture in OptiVitro® T cell serum-free Medium and medium 1, and the expansion folds were calculated. Data represents the mean of three replicates for each independent tests.
T Cell phenotypic characterization was performed in OptiVitro® T cell serum-free Medium and medium 1 on D13. Data represents the mean of three replicates for each independent tests.
T Cell viability was determined every 2-3 days throughout the culture in OptiVitro® T Cell Serum-free Medium TE07 and medium1. Data represents the mean of three replicates for each independent tests.
T Cell density was tested every 2-3 days throughout the culture in OptiVitro® T Cell Serum-free Medium TE07 and medium 1, and the expansion folds were calculated. Data represents the mean of three replicates for each independent tests.
T Cell density was tested every 2-3 days throughout the culture in OptiVitro® T Cell Serum-free Medium TE07 and medium 1, and the expansion folds were calculated. Data represents the mean of three replicates for each independent tests.
T Cell phenotypic characterization was performed in OptiVitro® T Cell Serum-free Medium TE07 and medium 1 on D13. Data represents the mean of three replicates for each independent tests.
The transduction efficiency of D5, D7, D9 and D13 during cell culture was tested. Compared with medium 1, OptiVitro® T Cell Serum-free Medium TE07 had higher transduction efficiency
Visit our FAQ database to get answers to various questions about using the product.
FAQ
Contact our technical expert team for professional product support and application guidance.
Contact us
